NCCN Guidelines® Insights: Gastrointestinal stromal tumors, version 2.2022: Featured updates to the NCCN Guidelines Guidelines
| Authors: | von Mehren, M.; Kane, J. M. 3rd; Riedel, R. F.; Sicklick, J. K.; Pollack, S. M.; Agulnik, M.; Bui, M. M.; Carr-Ascher, J.; Choy, E.; Connelly, M.; Dry, S.; Ganjoo, K. N.; Gonzalez, R. J.; Holder, A.; Homsi, J.; Keedy, V.; Kelly, C. M.; Kim, E.; Liebner, D.; McCarter, M.; McGarry, S. V.; Mesko, N. W.; Meyer, C.; Pappo, A. S.; Parkes, A. M.; Petersen, I. A.; Poppe, M.; Schuetze, S.; Shabason, J.; Spraker, M. B.; Zimel, M.; Bergman, M. A.; Sundar, H.; Hang, L. E. |
| Title: | NCCN Guidelines® Insights: Gastrointestinal stromal tumors, version 2.2022: Featured updates to the NCCN Guidelines |
| Abstract: | Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors. © National Comprehensive Cancer Network, Inc. 2022. |
| Keywords: | cancer chemotherapy; treatment response; gene mutation; genetics; mutation; sunitinib; advanced cancer; systemic therapy; gastrointestinal stromal tumor; imatinib; platelet derived growth factor alpha receptor; stem cell factor; stem cell factor receptor; gastrointestinal stromal tumors; proto-oncogene proteins c-kit; receptor, platelet-derived growth factor alpha; metastasis; practice guideline; chemosensitivity; mutational analysis; cancer resistance; protein tyrosine kinase inhibitor; inoperable cancer; disease exacerbation; randomized controlled trial (topic); phase 2 clinical trial (topic); meta analysis (topic); phase 3 clinical trial (topic); multicenter study (topic); regorafenib; humans; human; article; avapritinib; ripretinib |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 20 |
| Issue: | 11 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2022-11-01 |
| Start Page: | 1204 |
| End Page: | 1214 |
| Language: | English |
| DOI: | 10.6004/jnccn.2022.0058 |
| PUBMED: | 36351335 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 December 2022 -- Source: Scopus |
